Stockscreener 앱 받기
0.8762
0.14%
0.0012
시간 외 거래:
.89
0.0138
+1.57%
전일 마감가:
$0.875
열려 있는:
$0.883
하루 거래량:
132.73K
Relative Volume:
0.48
시가총액:
$33.21M
수익:
-
순이익/손실:
$-17.78M
주가수익비율:
-1.5954
EPS:
-0.5492
순현금흐름:
$-10.52M
1주 성능:
-7.77%
1개월 성능:
-28.47%
6개월 성능:
-69.15%
1년 성능:
-92.31%
1일 변동 폭
$0.85
$0.93
1주일 범위
$0.85
$1.03
52주 변동 폭
$0.85
$13.59
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
FBLG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.8762 | 33.21M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
FY2025 EPS Estimates for FibroBiologics Increased by Analyst - Defense World
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25… - Yahoo Finance
HC Wainwright Comments on FibroBiologics Q1 Earnings - Defense World
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt - GlobeNewswire Inc.
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair - GlobeNewswire
FibroBiologics announces advancement in results of brain tissue repair - TipRanks
Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair - MarketScreener
Major Breakthrough: FibroBiologics Confirms Brain Tissue Regeneration Success - Stock Titan
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Virtu Financial LLC Buys New Holdings in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges - Investing.com India
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Slashes Annual Losses by $5.3M as Key Clinical Trial Approaches - Stock Titan
Spotting Winners: TopBuild (NYSE:BLD) And Home Builders Stocks In Q4 - The Globe and Mail
FibroBiologics Announces 2025 Annual Meeting of Stockholders - GlobeNewswire
Biotech Pioneer FibroBiologics Reveals Massive 160+ Patent Portfolio at Upcoming Shareholder Meeting - Stock Titan
Applied Industrial (AIT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid FUBO and 1 Stock to Buy Instead - The Globe and Mail
Intuitive Machines Stock (LUNR) Lifts Off with 30% Surge Post Q4 Results - The Globe and Mail
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting - GlobeNewswire
FibroBiologics Announces Presentation on Innovative Fibroblast-Based Therapeutics at The German-Nordic Joint Extracellular Matrix Meeting - Nasdaq
FibroBiologics Reveals Groundbreaking Fibroblast Treatment Targeting 7 Major Diseases - Stock Titan
FBLG stock touches 52-week low at $0.98 amid sharp annual decline By Investing.com - Investing.com South Africa
FBLG stock touches 52-week low at $0.98 amid sharp annual decline - Investing.com Australia
Life Sciences Investor Forum Agenda Announced for March 13th - GlobeNewswire
FibroBiologics files patent application for fibroblast-based therapeutics - TipRanks
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics - GlobeNewswire
Could FibroBiologics' New Mitochondrial Therapy Patent Transform Treatment for Chronic Diseases? - StockTitan
FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital - Defense World
FibroBiologics and Charles River Announce Completion and - GlobeNewswire
FibroBiologics and Charles River complete master cell bank for clinical trials - TipRanks
FibroBiologics Completes Master Cell Bank for CYWC628 in Collaboration with Charles River Laboratories - Nasdaq
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic - GlobeNewswire
Can This New Cell Therapy Breakthrough Finally Solve the Diabetic Foot Ulcer Crisis? - Stock Titan
FibroBiologics (FBLG) Expected to Announce Earnings on Thursday - Defense World
Fibrobiologics stock plunges to 52-week low of $1.04 By Investing.com - Investing.com Australia
Fibrobiologics stock plunges to 52-week low of $1.04 - Investing.com India
FBLG: Analyst Day Provides In-Depth Overview of Pipeline… - Zacks Small Cap Research
FibroBiologics' (FBLG) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics’ (FBLG) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
Exploring Growth Opportunities In FibroBiologics Inc (NASDAQ: FBLG) - Stocks Register
D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Should This Give FibroBiologics Inc (NASDAQ: FBLG) Investors Sleepless Nights? - Stocks Register
FibroBiologics Inc (FBLG) stock analysis: A comprehensive overview - US Post News
FBLG (FibroBiologics Inc) may reap gains as insiders became active recently - Knox Daily
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView
FibroBiologics issues shares to fulfill commitment fee - MSN
FibroBiologics issues shares to fulfill commitment fee By Investing.com - Investing.com Australia
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fibrobiologics Inc 주식 (FBLG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
10.70%
자본화:
|
볼륨(24시간):